Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clotilde Wiel

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Oncoscience|October 27, 2015
Transport and senescenceDavid Bernard, Clotilde Wiel
Aging Cell|March 21, 2020
The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypesAudrey Griveau, Clotilde Wiel, Dorian V Ziegler, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2026
NRF2 activation by myeloid cell-derived oxidative stress induces SNAI-driven features of EMT in breast cancerMustafa Kaya, Olivia Johnsson, Nuttida Issdisai, et al.
Antioxidants (Basel, Switzerland)|January 27, 2021
Mitochondria-Targeted Antioxidants MitoQ and MitoTEMPO Do Not Influence BRAF-Driven Malignant Melanoma and KRAS-Driven Lung Cancer Progression in MiceKristell Le Gal, Clotilde Wiel, Mohamed X Ibrahim, et al.
Frontiers in Oncology|June 17, 2024
Assessing the prognostic value of <i>KRAS</i> mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysisElla A Eklund, Ali Mourad, Clotilde Wiel, et al.
Iscience|August 3, 2023
Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factorElin Schoultz, Shawn Liang, Therese Carlsson, et al.
Cancers|May 14, 2022
<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung CancerElla A Eklund, Clotilde Wiel, Henrik Fagman, et al.
JTO Clinical and Research Reports|September 10, 2025
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish CohortElla A Eklund, Sama I Sayin, Jonas Smith Jonsson, et al.
Aging Cell|September 10, 2020
Targeting RAS-converting enzyme 1 overcomes senescence and improves progeria-like phenotypes of ZMPSTE24 deficiencyHaidong Yao, Xue Chen, Muhammad Kashif, et al.
Free Radical Biology & Medicine|September 9, 2022
Biotinylation of an acetylenic tricyclic bis(cyanoenone) lowers its potency as an NRF2 activator while creating a novel activity against BACH1Rita Moreno, Laura Casares, Maureen Higgins, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Oncoscience|October 27, 2015
Transport and senescenceDavid Bernard, Clotilde Wiel
Aging Cell|March 21, 2020
The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypesAudrey Griveau, Clotilde Wiel, Dorian V Ziegler, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2026
NRF2 activation by myeloid cell-derived oxidative stress induces SNAI-driven features of EMT in breast cancerMustafa Kaya, Olivia Johnsson, Nuttida Issdisai, et al.
Antioxidants (Basel, Switzerland)|January 27, 2021
Mitochondria-Targeted Antioxidants MitoQ and MitoTEMPO Do Not Influence BRAF-Driven Malignant Melanoma and KRAS-Driven Lung Cancer Progression in MiceKristell Le Gal, Clotilde Wiel, Mohamed X Ibrahim, et al.
Frontiers in Oncology|June 17, 2024
Assessing the prognostic value of <i>KRAS</i> mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysisElla A Eklund, Ali Mourad, Clotilde Wiel, et al.
Iscience|August 3, 2023
Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factorElin Schoultz, Shawn Liang, Therese Carlsson, et al.
Cancers|May 14, 2022
<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung CancerElla A Eklund, Clotilde Wiel, Henrik Fagman, et al.
JTO Clinical and Research Reports|September 10, 2025
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish CohortElla A Eklund, Sama I Sayin, Jonas Smith Jonsson, et al.
Aging Cell|September 10, 2020
Targeting RAS-converting enzyme 1 overcomes senescence and improves progeria-like phenotypes of ZMPSTE24 deficiencyHaidong Yao, Xue Chen, Muhammad Kashif, et al.
Free Radical Biology & Medicine|September 9, 2022
Biotinylation of an acetylenic tricyclic bis(cyanoenone) lowers its potency as an NRF2 activator while creating a novel activity against BACH1Rita Moreno, Laura Casares, Maureen Higgins, et al.
Pageof 4